Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | CDO | July 07, 2026 | July 09, 2026 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Chief Development Officer | July 19, 2022 | October 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.29 · Expires 2036-07-06 | Direct | 48,285 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 48,285 · Balance 48,285 F1: The option grant described in this Form 4 filing vests as to 25% of the original shares on July 7, 2027 and as to an additional 6.25% of the original shares each successive quarter and until July 7, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant described in this Form 4 filing vests as to 25% of the original shares on July 7, 2027 and as to an additional 6.25% of the original shares each successive quarter and until July 7, 2030.
Evelo Biosciences, Inc.
Report date July 19, 2022 · Filed October 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2032-07-19 | Direct | 115,000 |
Reported balance
After 2022-07-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-19 · Grant · Acquired 115,000 · Balance 115,000 F1: The option will vest as to 50% of the underlying shares on the first anniversary of the date of grant, and as to the remaining 50% of the underlying shares on the second anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest as to 50% of the underlying shares on the first anniversary of the date of grant, and as to the remaining 50% of the underlying shares on the second anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 20:09 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 48,285 | $5.29 Strike: $5.29 | $255,427.65 |
DisclosureSEC source: 0001108205-26-000090 · wk-form4_1783627796.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,285 Underlying: Common Stock · 48,285 shares Expires 2036-07-06 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on July 7, 2027 and as to an additional 6.25% of the original shares each successive quarter and until July 7, 2030. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 20:03 UTC | CURIS INC CRIS · Entity 8401 | ConversionSeries B Convertible Preferred Stock · Derivative | 50 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001108205-26-000040 · wk-form4_1774296236.xml · derivative · entry 2 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.exercise_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.expiration_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 20:03 UTC | CURIS INC CRIS · Entity 8401 | ConversionCommon Stock | 66,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001108205-26-000040 · wk-form4_1774296236.xml · nonDerivative · entry 1 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:22 UTC | CURIS INC CRIS · Entity 8401 | GrantSeries C Warrant (right to buy) · Derivative | 66,667 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001108205-26-000028 · wk-form4_1773865326.xml · derivative · entry 4 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires 2027-07-08 F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F5 · derivative.exercise_date: The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:22 UTC | CURIS INC CRIS · Entity 8401 | GrantSeries B Warrant (right to buy) · Derivative | 66,667 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001108205-26-000028 · wk-form4_1773865326.xml · derivative · entry 3 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires not disclosed F4 · derivative.exercise_price: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days. F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F4 · derivative.exercise_date: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days. F4 · derivative.expiration_date: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:22 UTC | CURIS INC CRIS · Entity 8401 | GrantSeries A Warrant (right to buy) · Derivative | 66,667 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001108205-26-000028 · wk-form4_1773865326.xml · derivative · entry 2 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires 2031-01-08 F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F3 · derivative.exercise_date: Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:22 UTC | CURIS INC CRIS · Entity 8401 | GrantSeries B Convertible Preferred Stock · Derivative | 50 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001108205-26-000028 · wk-form4_1773865326.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50 Underlying: Common Stock · 66,667 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.exercise_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). F1 · derivative.expiration_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:12 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 135,000 | $3.13 Strike: $3.13 | $422,550.00 |
DisclosureSEC source: 0001108205-25-000063 · wk-form4_1747944748.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2035-01-27 F1 · date: This option grant, as disclosed in Curis Inc.'s 2025 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 28, 2025, contingent upon shareholder approval of Curis's Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if Amendment No. 1 to the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 20, 2025, at the 2025 annual meeting of shareholders, Curis's shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Plan. F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:08 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 15,000 | $3.13 Strike: $3.13 | $46,950.00 |
DisclosureSEC source: 0001108205-25-000014 · wk-form4_1738271330.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-01-27 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:10 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 40,700 | $11.62 Strike: $11.62 | $472,934.00 |
DisclosureSEC source: 0001108205-24-000053 · wk-form4_1716495039.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,700 Underlying: Common Stock · 40,700 shares Expires 2034-01-18 F1 · date: This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 19, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to, among other things, increase the number of shares authorized for issuance thereunder and increase the per participant limit on the number of shares subject to awards that can be granted annually to participants in the plan; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan. F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 19, 2025 and as to an additional 6.25% of the original shares each successive quarter and until January 19, 2028. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:12 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 500,000 | $0.83 Strike: $0.83 | $415,000.00 |
DisclosureSEC source: 0001108205-23-000046 · wf-form4_168314471048406.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-04-30 F1 · derivative.exercise_date: This stock option vests over four years, with 25% of the original 500,000 shares underlying the award vesting on May 1, 2024 and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to continued service. Read SEC document |
| July 19, 2022 Filed Oct 14, 2022 16:32 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001694665-22-000134 · wf-form4_166577953055922.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2032-07-19 F1 · derivative.exercise_date: The option will vest as to 50% of the underlying shares on the first anniversary of the date of grant, and as to the remaining 50% of the underlying shares on the second anniversary of the date of grant. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 16:56 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001694665-22-000019 · wf-form4_164280216664623.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to continued employment on such dates. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 17:28 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001694665-21-000019 · wf-form4_161195929825887.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: This option will vest as to 25% of the total grant on January 4, 2022 and the remainder vesting thereafter in thirty-six (36) substantially equal monthly installments, subject to continued employment on such dates. Read SEC document |
| January 27, 2021 Filed Feb 1, 2021 17:07 UTC Amendment | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001694665-21-000029 · wf-form4a_161221722128198.xml · derivative · entry 2 Zung Jonathan B. · CIK 0001837972 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_date: These Restricted Stock Units will vest in full on the third anniversary of the grant date, January 27, 2024, subject to continued employment on such date. F2 · derivative.expiration_date: These Restricted Stock Units will vest in full on the third anniversary of the grant date, January 27, 2024, subject to continued employment on such date. Read SEC document |
| January 27, 2021 Filed Feb 1, 2021 17:07 UTC Amendment | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001694665-21-000029 · wf-form4a_161221722128198.xml · derivative · entry 1 Zung Jonathan B. · CIK 0001837972 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: This option will vest as to 25% of the total grant on January 4, 2022 and as to the remaining 75% vesting thereafter in thirty-six (36) substantially equal monthly installments, subject to continued employment on such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.